Skip to main content
Caplight Logo









Xilis

Xilis

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://xilis.com/

Last Round

Series A

Extension

Jul 13, 2022

Total Funding Raised

$28.75M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Xilis is a biotechnology company that develops MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

precision oncologyorganoidtumor modelingdrug discoverypatient-derived organoidsex vivopersonalized medicineclinical trial optimizationdrug response testingorgan-on-a-chipfunctional genomicscomputational biologypreclinical modelingbiotech servicestranslational research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xilis Comparables

Compare Xilis with similar companies based on industry and business-model similarity.

Xilis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AimingMed
83%
Keliomics
81%
Shanghai Wanheyuan Biotechnology Co., Ltd.
79%

Xilis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJul 13, 2022
DebtJul 8, 2021
SeedMay 21, 2020
SeedDec 19, 2019

Xilis Investors

Notable investors and investment history

Xilis investors
InvestorRounds
EQT Life SciencesDebt, Series A Extension
GVDebt, Series A Extension
The Duke EndowmentDebt
Alix VenturesDebt, Series A Extension
Catalio Capital ManagementDebt, Series A Extension
Two Sigma VenturesDebt, Series A Extension
Pear VCSeries A Extension, Seed, Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 45% MoM.

  • Jun 18, 2026

    Monthly visitors grew 480% MoM to 2.2K.

Xilis Filings

Explore SEC and related filing metadata, where available.

Xilis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Xilis's valuation, stock price, and market status.

Is Xilis a public or private company?

Xilis is a private company.

What is the current stock price of Xilis?

Xilis is a private company with no public stock price. No recent secondary market data is available.

How much is Xilis worth (valuation)?

Valuation information for Xilis is not publicly available.

Can I buy Xilis stock?

Xilis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Xilis's last funding round?

Xilis's most recent funding round was Series A Extension on July 13, 2022.

Who are the main investors in Xilis?

Key investors in Xilis include Mubadala Capital, FPV Ventures.

Will Xilis IPO soon?

No public IPO plans have been announced for Xilis.

How can I track Xilis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Xilis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range9
Year Founded2019
Last FundingJul 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?